Ischemia Reperfusion Injury Market Report 2026

The ischemia reperfusion injury market size has grown strongly in recent years. It will grow from $1.67 billion in 2025 to $1.79 billion in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to rising incidence of cardiovascular diseases, increasing number of organ transplant procedures, growing prevalence of stroke and heart attack cases, advancement in acute care infrastructure, increased use of pharmacological therapies.

The ischemia reperfusion injury market size is expected to see strong growth in the next few years. It will grow to $2.38 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to growth in stem cell and gene therapy research, rising adoption of non-pharmacological conditioning therapies, increasing investment in critical care technologies, expanding clinical trials for mitochondrial protective agents, improving awareness of ischemia-reperfusion mechanisms. Major trends in the forecast period include AI-enabled prediction of ischemia-reperfusion injury outcomes, precision therapeutics for cellular and mitochondrial protection, data-driven clinical decision support systems, connected monitoring of tissue perfusion and oxygenation, advanced manufacturing of targeted therapeutics.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the ischemia-reperfusion injury market in the coming years. Cardiovascular diseases encompass a range of disorders affecting the heart and blood vessels, including coronary artery disease, heart failure, and stroke. This rising prevalence is largely attributed to unhealthy lifestyle habits and an aging population. Diets high in saturated fats, sugar, and salt, combined with insufficient physical activity, have led to increased rates of obesity, hypertension, and diabetes, all of which are major risk factors for cardiovascular diseases. Ischemia-reperfusion injury worsens the progression of cardiovascular diseases by intensifying tissue damage through oxidative stress, inflammation, and cell death, ultimately reducing cardiac function and raising the risk of heart failure and other complications. For example, in October 2024, the Centers for Disease Control and Prevention, a US-based public health agency, reported that 919,032 people died from cardiovascular disease in 2023, accounting for one in three deaths. Consequently, the rising prevalence of cardiovascular diseases is propelling the growth of the ischemia-reperfusion injury market.

The increasing frequency of organ transplantation is expected to drive the growth of the ischemia-reperfusion injury market in the coming years. Organ transplantation involves the surgical transfer of a healthy organ from a donor to a recipient to replace a damaged or failing organ. The rising frequency of organ transplantation is attributed to advancements in medical technology and the growing number of patients experiencing organ failure. Improvements in surgical techniques, immunosuppressive therapies, and organ preservation have significantly enhanced the success rates of organ transplants. Ischemia-reperfusion injury (IRI) can be reduced during organ transplantation by using advanced preservation methods that limit damage occurring during ischemia, thereby improving the survival and function of the transplanted organ upon reperfusion. For example, in January 2024, the Organ Procurement and Transplantation Network, a US-based Department of Health and Human Services program overseeing the nation’s organ donation and transplantation system, reported that organ transplants from living and deceased donors reached 46,632 in 2023, marking an 8.7 percent increase compared with 2022. Of these, 39,679 procedures were from deceased donors, reflecting an 8.9 percent rise over the previous year. Consequently, the growing frequency of organ transplantation is fueling the expansion of the ischemia-reperfusion injury market.

Major companies in the ischemia-reperfusion injury market are concentrating on innovative therapeutics, such as dual-acting stroke treatments, to enhance patient recovery, minimize disability, and improve overall treatment outcomes. Dual-acting neuroprotective therapeutics are advanced small-molecule agents that combine selective NMDA receptor modulation with antioxidant free-radical scavenging, providing benefits such as reducing reperfusion-induced neuronal damage, enhancing post-occlusion tissue survival, and supporting functional recovery. For example, in July 2025, GNT Pharma, a South Korea-based biopharmaceutical company, obtained regulatory approval to initiate multinational Phase 3 clinical trials for Nelonemdaz, a next-generation dual-acting neuroprotective drug aimed at reducing neuronal injury in patients undergoing endovascular thrombectomy for acute ischemic stroke. This therapy features selective inhibition of NMDA receptor-mediated excitotoxicity along with potent free-radical scavenging to limit oxidative damage. Nelonemdaz enhances neuroprotection, functional recovery, and post-reperfusion outcomes in ischemic stroke patients.

Major companies operating in the ischemia reperfusion injury market are Pfizer Inc, Novartis AG, AstraZeneca PLC, Bristol Myers Squibb, F. Hoffmann-La Roche Ltd, Sanofi, Merck KGaA, Takeda Pharmaceutical Company, Bayer AG, Amgen Inc, Otsuka Pharmaceutical Co Ltd, Simcere Innovation Inc, Faron Pharmaceuticals Oy, Faraday Pharmaceuticals Inc, Prolong Pharmaceuticals LLC, Angion Biomedica Corp, CalciMedica Inc, Athersys Inc, Oxitope Pharma BV, LUCA Science Inc.

North America was the largest region in the ischemia reperfusion injury market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemia reperfusion injury market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ischemia reperfusion injury market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the ischemia reperfusion injury market by increasing costs of imported pharmacological agents, medical devices, and advanced therapy components used in acute and critical care. Segments such as pharmacological therapies and gene and stem cell-based interventions are most affected, with north america and asia-pacific experiencing higher supply chain sensitivity due to cross-border sourcing. However, tariffs have encouraged localized manufacturing, strengthened domestic supply chains, and supported investments in regional production capabilities, contributing to long-term market resilience.

The ischemia reperfusion injury market research report is one of a series of new reports that provides ischemia reperfusion injury market statistics, including ischemia reperfusion injury industry global market size, regional shares, competitors with a ischemia reperfusion injury market share, detailed ischemia reperfusion injury market segments, market trends and opportunities, and any further data you may need to thrive in the ischemia reperfusion injury industry. This ischemia reperfusion injury market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ischemia-reperfusion injury refers to the tissue damage that occurs when blood flow is restored to tissue after a period of ischemia (oxygen deprivation). The reestablishment of circulation can lead to inflammation and oxidative damage. This injury involves pathophysiological processes that produce both local and systemic effects.

The primary treatment approaches for ischemia-reperfusion injury include pharmacological and non-pharmacological therapies. Pharmacological therapy uses medications to prevent or manage conditions by targeting underlying mechanisms such as oxidative stress, inflammation, and cell death. These treatments are applied in various conditions, including cardiovascular diseases, stroke, organ transplantation, heart attack, and diabetes. The recipients of these therapies include hospitals, clinics, ambulatory services, and nursing homes.

The ischemia-reperfusion injury market consists of revenues earned by entities by providing services such as diagnostic imaging services, surgical interventions, pharmacological treatment services, rehabilitation and physical therapy, research, and clinical trial services. The market value includes the value of related goods sold by the service provider or included within the service offering. The ischemia-reperfusion injury market also includes sales of products including pharmaceuticals and therapeutics, medical devices, diagnostic tools and kits, reperfusion equipment, research tools, and reagents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.